Literature DB >> 16861635

Modulation of host immune responses by the cytolethal distending toxin of Helicobacter hepaticus.

Jason S Pratt1, Kacey L Sachen, Heather D Wood, Kathryn A Eaton, Vincent B Young.   

Abstract

Persistent murine infection with Helicobacter hepaticus leads to chronic gastrointestinal inflammation and neoplasia in susceptible strains. To determine the role of the virulence factor cytolethal distending toxin (CDT) in the pathogenesis of this organism, interleukin-10-deficient (IL-10-/-) mice were experimentally infected with wild-type H. hepaticus and a CDT-deficient isogenic mutant. Both wild-type H. hepaticus and the CDT-deficient mutant successfully colonized IL-10-/- mice, and they reached similar tissue levels by 6 weeks after infection. Only animals infected with wild-type type H. hepaticus developed significant typhlocolitis. However, by 4 months after infection, the CDT-deficient mutant was no longer detectable in IL-10-/- mice, whereas wild-type H. hepaticus persisted for the 8-month duration of the experiment. Animals infected with wild-type H. hepaticus exhibited severe typhlocolitis at 8 months after infection, while animals originally challenged with the CDT-deficient mutant had minimal cecal inflammation at this time point. In follow-up experiments, animals that cleared infection with the CDT-deficient mutant were protected from rechallenge with either mutant or wild-type H. hepaticus. Animals infected with wild-type H. hepaticus developed serum immunoglobulin G1 (IgG1) and IgG2c responses against H. hepaticus, while animals challenged with the CDT-deficient mutant developed significantly lower IgG2c responses and failed to mount IgG1 responses against H. hepaticus. These results suggest that CDT plays a key immunomodulatory role that allows persistence of H. hepaticus and that in IL-10-/- mice this alteration of the host immune response results in the development of colitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16861635      PMCID: PMC1539592          DOI: 10.1128/IAI.00503-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Actinobacillus actinomycetemcomitans cytolethal distending toxin (Cdt): evidence that the holotoxin is composed of three subunits: CdtA, CdtB, and CdtC.

Authors:  Bruce J Shenker; Dave Besack; Terry McKay; Lisa Pankoski; Ali Zekavat; Donald R Demuth
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

2.  The Haemophilus ducreyi cytolethal distending toxin induces DNA double-strand breaks and promotes ATM-dependent activation of RhoA.

Authors:  Teresa Frisan; Ximena Cortes-Bratti; Esteban Chaves-Olarte; Bo Stenerlöw; Monica Thelestam
Journal:  Cell Microbiol       Date:  2003-10       Impact factor: 3.715

3.  An N-terminal segment of the active component of the bacterial genotoxin cytolethal distending toxin B (CDTB) directs CDTB into the nucleus.

Authors:  Shuichi Nishikubo; Masaru Ohara; Yoko Ueno; Masae Ikura; Hidemi Kurihara; Hitoshi Komatsuzawa; Eric Oswald; Motoyuki Sugai
Journal:  J Biol Chem       Date:  2003-08-28       Impact factor: 5.157

Review 4.  The basis of persistent bacterial infections.

Authors:  Mikael Rhen; Sofia Eriksson; Mark Clements; Sven Bergström; Staffan J Normark
Journal:  Trends Microbiol       Date:  2003-02       Impact factor: 17.079

5.  Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation.

Authors:  Bettina Gebert; Wolfgang Fischer; Evelyn Weiss; Reinhard Hoffmann; Rainer Haas
Journal:  Science       Date:  2003-08-22       Impact factor: 47.728

6.  Gastroenteritis in NF-kappaB-deficient mice is produced with wild-type Camplyobacter jejuni but not with C. jejuni lacking cytolethal distending toxin despite persistent colonization with both strains.

Authors:  James G Fox; Arlin B Rogers; Mark T Whary; Zhongming Ge; Nancy S Taylor; Sandy Xu; Bruce H Horwitz; Susan E Erdman
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

7.  Caspase-2 and caspase-7 are involved in cytolethal distending toxin-induced apoptosis in Jurkat and MOLT-4 T-cell lines.

Authors:  Masaru Ohara; Tomonori Hayashi; Yoichiro Kusunoki; Mutsumi Miyauchi; Takashi Takata; Motoyuki Sugai
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

8.  CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice.

Authors:  Susan E Erdman; Varada P Rao; Theofilos Poutahidis; Melanie M Ihrig; Zhongming Ge; Yan Feng; Michal Tomczak; Arlin B Rogers; Bruce H Horwitz; James G Fox
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

9.  Immunosuppressive and proinflammatory activities of the VacA toxin of Helicobacter pylori.

Authors:  Cesare Montecucco; Marina de Bernard
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms.

Authors:  Marianna Boncristiano; Silvia Rossi Paccani; Silvia Barone; Cristina Ulivieri; Laura Patrussi; Dag Ilver; Amedeo Amedei; Mario Milco D'Elios; John L Telford; Cosima T Baldari
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  42 in total

1.  Ulcerative typhlocolitis associated with Helicobacter mastomyrinus in telomerase-deficient mice.

Authors:  K A Eaton; J S Opp; B M Gray; I L Bergin; V B Young
Journal:  Vet Pathol       Date:  2010-10-06       Impact factor: 2.221

Review 2.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models.

Authors:  Sandra Nell; Sebastian Suerbaum; Christine Josenhans
Journal:  Nat Rev Microbiol       Date:  2010-07-12       Impact factor: 60.633

3.  Immune response to cytolethal distending toxin of Aggregatibacter actinomycetemcomitans in periodontitis patients.

Authors:  E S Ando; L A De-Gennaro; M Faveri; M Feres; J M DiRienzo; M P A Mayer
Journal:  J Periodontal Res       Date:  2010-03-09       Impact factor: 4.419

4.  Diverse phage-encoded toxins in a protective insect endosymbiont.

Authors:  Patrick H Degnan; Nancy A Moran
Journal:  Appl Environ Microbiol       Date:  2008-09-12       Impact factor: 4.792

Review 5.  Cytolethal distending toxin: a conserved bacterial genotoxin that blocks cell cycle progression, leading to apoptosis of a broad range of mammalian cell lineages.

Authors:  Rasika N Jinadasa; Stephen E Bloom; Robert S Weiss; Gerald E Duhamel
Journal:  Microbiology (Reading)       Date:  2011-05-12       Impact factor: 2.777

6.  Increased presence of effector lymphocytes during Helicobacter hepaticus-induced colitis.

Authors:  Sarah J McCaskey; Elizabeth A Rondini; Jonathan F Clinthorne; Ingeborg M Langohr; Elizabeth M Gardner; Jenifer I Fenton
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

7.  Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice.

Authors:  Laura Harris; Patricia Senagore; Vincent B Young; Laura R McCabe
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-19       Impact factor: 4.052

8.  Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice.

Authors:  Maciej Chichlowski; Julie M Sharp; Deborah A Vanderford; Matthew H Myles; Laura P Hale
Journal:  Comp Med       Date:  2008-12       Impact factor: 0.982

9.  Cytolethal distending toxin type I and type IV genes are framed with lambdoid prophage genes in extraintestinal pathogenic Escherichia coli.

Authors:  István Tóth; Jean-Philippe Nougayrède; Ulrich Dobrindt; Terence Neil Ledger; Michèle Boury; Stefano Morabito; Tamaki Fujiwara; Motoyuki Sugai; Jörg Hacker; Eric Oswald
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

10.  Colitis-induced bone loss is gender dependent and associated with increased inflammation.

Authors:  Regina Irwin; Taehyung Lee; Vincent B Young; Narayanan Parameswaran; Laura R McCabe
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.